Valbiotis successfully raises €6.9 million in capital for its expansion

Valbiotis, a French laboratory specializing in dietary supplements, announced the successful completion of its capital increase, raising €6.9 million. This transaction, which attracted strong interest from current shareholders, supports the company's commercial growth. Sébastien Peltier, Chairman and co-founder, actively participated in this fundraising through his personal holding company, Djanka Investissement.

The funds acquired will be primarily allocated to marketing, communications, and international expansion. Sixty percent of the proceeds will be used to strengthen these initiatives, while 30 percent will be allocated to operational cash flow in France. The remainder will be used to expand the network of medical attachés.

The IPO of the new shares is scheduled for June 30, 2025, increasing the share capital to €2,369,823.40, divided into 23,698,234 shares.